2017
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome
Zuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Modern Pathology 2017, 31: 350-357. PMID: 29027536, DOI: 10.1038/modpathol.2017.121.Peer-Reviewed Original ResearchConceptsAtypical proliferative serous tumorNon-invasive implantsDisease-specific survivalSerous borderline tumorsHigh recurrence rateWorse disease-specific survivalStage IIIC diseaseKRAS mutationsInvasive implantsBRAF V600E mutationBorderline tumorsSerous tumorsRecurrence rateIIIC diseaseClinical outcomesHistological subtypesPrognostic indicatorExtraovarian implantsV600E mutationLow-grade serous carcinomaUnfavorable disease-specific survivalAdverse clinical outcomesHigher stage diseaseSignificant prognostic indicatorBRAF mutation frequency
2013
A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria
Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Archives Of Pathology & Laboratory Medicine 2013, 138: 213-9. PMID: 24164555, DOI: 10.5858/arpa.2012-0617-oa.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinomaCohort StudiesConnecticutFemaleHospitals, UniversityHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMammary Glands, HumanMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm ProteinsPractice Guidelines as TopicReceptor, ErbB-2Retrospective StudiesSocieties, MedicalUnited StatesUnited States Food and Drug Administration
2010
HER-2/NEU overexpression in vulvar Paget disease: the Yale experience
Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.Peer-Reviewed Original ResearchConceptsVulvar Paget's diseasePaget's diseaseNeu overexpressionOutcome dataHER-2/neu expressionHER-2/neuEfficacy of trastuzumabExtensive reconstructive proceduresHigh recurrence rateMedical record searchInteresting treatment optionSurgical treatmentRecurrence rateTreatment optionsNeu expressionClinical trialsReconstructive proceduresTissue microarrayPatientsRecord searchTumor samplesYale experienceDiseaseNeuStaining results
2002
Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma A Search for the Early Precursors of Papillary Cancer
Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M, Rosai J, Tallini G. Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma A Search for the Early Precursors of Papillary Cancer. American Journal Of Pathology 2002, 160: 2157-2167. PMID: 12057919, PMCID: PMC1850819, DOI: 10.1016/s0002-9440(10)61164-9.Peer-Reviewed Original ResearchMeSH Keywords3T3 CellsAnimalsBase SequenceCarcinoma, PapillaryCloning, MolecularDrosophila ProteinsGene Expression Regulation, NeoplasticGenetic MarkersHumansMembrane ProteinsMiceMolecular Sequence DataNeoplasm InvasivenessNuclear Receptor CoactivatorsOncogene ProteinsOncogene Proteins, FusionPatched ReceptorsPatched-1 ReceptorProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-retRabbitsReceptor Protein-Tyrosine KinasesReceptors, Cell SurfaceReverse Transcriptase Polymerase Chain ReactionThyroid NeoplasmsThyroid NoduleTranscription FactorsConceptsLaser capture microdissectionPapillary cancerRET/PTC1RET immunoreactivityThyroid nodulesCarcinoma featuresMicroscopic fociPapillary carcinomaInvasive papillary cancerCytological alterationsReverse transcriptase-polymerase chain reactionRET activationRET/PTC3 rearrangementsTranscriptase-polymerase chain reactionRET/PTC3Analysis of clonalityRET/PTC oncogene activationPrecursor lesionsEntire lesionTumor fociPolyclonal tumorsAdenomatous nodulesMorphological changesSame tumorMorphological signs